Results 171 to 180 of about 31,170 (214)

Vision rehabilitation of post-Descemet membrane endothelial keratoplasty Pseudomonas keratitis utilizing losartan ophthalmic solution and scleral contact lens: a case report. [PDF]

J Med Case Rep
Erdinest N, Shemesh N, London N, Lavy I.
europepmc   +1 more source

Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: the 'MOI-A' study; a randomised, phase 2/pilot, dose-escalating trial. [PDF]

BMJ Open
Haji Sadeghi M, Cohen J, Williams B, Wilkinson A, Sumpter S, Simms L, Huang C, Pugh K, Heath C, Sangiorgi L, Gurioli F, Gnoli M, Moroni A, Leopardi MP, Del Coco C, Bishop N.   +15 more
europepmc   +1 more source

Beyond blood pressure: the renin-angiotensin system as an innovative driver and therapeutic target in pathological scarring. [PDF]

Front Pharmacol
Shi BH, Zhang XG, Fang QQ, Xu K, Chen XL, Tan WQ, Wang SJ.   +6 more
europepmc   +1 more source

Effect of Antihypertensive Losartan on Ca²⁺ Mobilization in the Aorta of Middle-Aged Spontaneously Hypertensive Female Rats. [PDF]

J Cardiovasc Dev Dis
Rastogi S, Liaw J, Zhai Y, Karpova T, Gu L, Nunes K.   +5 more
europepmc   +1 more source

Effect of enalapril and losartan on the expression of genes involved in inflammation, fibrogenesis, and apoptosis in orbital fibroblasts of graves' ophthalmopathy. [PDF]

BMC Res Notes
Sanie-Jahromi F, Khademi B, Owji N.
europepmc   +1 more source

The renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers

Prasad D, Feltham G, De Giorgi R, Costi S, Fox E, Gillespie AL, Reinecke A.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Losartan

Drugs, 2012
Marit D Moen, Moen Marit D, Wagstaff Antona J   +2 more
exaly   +4 more sources

Losartan

Drugs, 2003
Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist. Losartan 50 or 100 mg/day was significantly more effective than placebo in reducing the incidence of a doubling of serum creatinine, end-stage renal disease (ESRD) or death (43.5% vs 47.1%, p = 0.02) in a pivotal, well designed trial (Reduction of Endpoints ...
Christopher I, Carswell, Karen L, Goa
  +5 more sources

Losartan

Reactions Weekly, 2023
  +4 more sources